56. ベーチェット病 Disease details / Clinical trials / Drug dev / DR info
臨床試験数 : 81 / 薬物数 : 107 - (DrugBank : 30) / 標的遺伝子数 : 36 - 標的パスウェイ数 : 116
薬物ごとの開発者(Primary Sponsor)、臨床試験情報(抜粋)です。
2387066
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
3400935113276
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
8699505952864
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
AIN457
Novartis Farmacéutica, S.A.
2010 - EUCTR2009-013901-33-ES Austria;France;Germany;Greece;Spain;
2009 Phase 3 EUCTR2009-011237-27-ES Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharma Services AG
2010 - EUCTR2009-013901-33-GR Austria;France;Germany;Greece;Spain;
2010 - EUCTR2009-013901-33-FR Austria;France;Germany;Greece;Spain;
2010 - EUCTR2009-013901-33-DE Austria;France;Germany;Greece;Spain;
2009 - EUCTR2009-013901-33-AT Austria;France;Germany;Greece;Spain;
2009 - EUCTR2009-011237-27-DE Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-AT Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharma Services Ag
2009 - EUCTR2009-011237-27-HU Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-GR Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-FR Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharmaceuticals
2009 Phase 3 NCT00995709 Austria;Brazil;Egypt;France;Germany;Greece;Hong Kong;Hungary;India;Israel;Italy;Jordan;Korea, Republic of;Saudi Arabia;Singapore;Spain;Switzerland;Taiwan;Tunisia;Turkey;United States;
AMG 407
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
AMG-407
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
AMG407
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Adalimumab
AbbVie (prior sponsor, Abbott)
2010 Phase 3 NCT01243671 Japan;
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
2020 Phase 4 ChiCTR1900027147 China;
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
The First Affiliated Hospital, College of Medicine, Zhejiang University
2021 Phase 4 ChiCTR2100045463 China;
Allogeneic Stem Cell Transplant
Northwestern University
2003 Phase 1 NCT00278512 United States;
Alpha interferon
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2011 Phase 1/Phase 2 NCT01441076 United States;
Apremilast
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Amgen
2021 Phase 3 NCT04528082 France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT02307513 France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Lebanon;Turkey;United States;
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Apremilast (CC-10004)
Amgen
2009 Phase 2 NCT00866359 Turkey;United States;
Autologous Stem Cell Transplant
Northwestern University
2003 Phase 1 NCT00278512 United States;
Autologous Stem Cell Transplantation
Tehran University of Medical Sciences
2007 Phase 1 NCT00550498 Iran, Islamic Republic of;
BFGF
Turkish Ophthalmology Society
2011 - NCT01720628 Turkey;
CC-10004
Amgen Inc.
2015 Phase 3 EUCTR2014-002108-25-DE France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
Celgene Corporation
2016 Phase 3 EUCTR2014-002108-25-GR France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
2015 Phase 3 EUCTR2014-002108-25-IT France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
Canakinumab
Novartis Pharmaceuticals
2016 Phase 2 NCT02756650 Turkey;
Colchicine
Ipekyolu Ilac Ltd. Sti
2019 Phase 2 NCT03888846 Turkey;
Tehran University of Medical Sciences
2002 Phase 2 NCT00700297 Iran, Islamic Republic of;
Cyclophosphamide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03371095 -
Cyclosporin A
University Hospital Tuebingen
2004 Phase 3 NCT00167583 Germany;
Cyclosporine
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
Yokohama City University Hospital
2017 - JPRN-UMIN000025451 Japan;
Cyclosporine Pill
Peking Union Medical College Hospital
2017 Phase 3 NCT03209219 China;
Cytotoxic Combination
Tehran University of Medical Sciences
2006 Phase 2 NCT00664599 Iran, Islamic Republic of;
Daclizumab
National Eye Institute (NEI)
1999 Phase 2 NCT00001865 United States;
Dextrose
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
Entecavir
Saitama Medical University
2016 - JPRN-UMIN000020029 Japan;
Etanercept, Methotrexate, Prednisolone
Tehran University of Medical Sciences
2010 - NCT00931957 Iran, Islamic Republic of;
Flucinolone acetonide
Asan Medical Center
2008 Phase 4 NCT00720928 Korea, Republic of;
GSK1070806
Cambridge University Hospitals NHS Foundation Trust
2018 Phase 2 NCT03522662 United Kingdom;
Gevokizumab
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 Phase 3 NCT01965145 Korea, Republic of;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
XOMA (US) LLC
2014 Phase 3 NCT02258867 United States;
Golimumab (GOL)
Wenjie Zheng
2020 Phase 2 NCT04218565 China;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Hemay005
Tianjin Hemay Pharmaceutical Co.,Ltd
2020 Phase 2 NCT04609397 China;
Hydroxychloroquine
Assiut University
2018 - NCT04022421 Egypt;
INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Ilaris
University Hospital of Tübingen
2011 - EUCTR2010-024152-29-DE Germany;
Infliximab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03371095 -
Janssen Korea, Ltd., Korea
2015 Phase 3 NCT02505568 Korea, Republic of;
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Yokohama City University Hospital
2017 - JPRN-UMIN000025451 Japan;
Interferon alpha-2a
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
Interferon-alpha2a
University Hospital Tuebingen
2004 Phase 3 NCT00167583 Germany;
Intravitreal Infliximab
Cairo University
2013 Phase 1/Phase 2 NCT02620618 -
J1081
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Low-dose IL-2
Peking University People's Hospital
2019 Phase 2 NCT04065672 China;
MEDROL - 4 MG COMPRESSE 30 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
METILPREDNISOLONE SODIO SUCCINATO
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Methylorednisolone
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Otezla
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
2015 Phase 3 EUCTR2014-002108-25-DE France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Pentoxifylline
Ipekyolu Ilac Ltd. Sti
2019 Phase 2 NCT03888846 Turkey;
Prednisolone
Castle Study Group
2013 - JPRN-UMIN000012469 Japan;
Remicade
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
RhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services Ag
2009 - EUCTR2009-011237-27-FR Austria;France;Germany;Greece;Hungary;Italy;Spain;
Rituximab
Tehran University of Medical Sciences
2006 Phase 2 NCT00664599 Iran, Islamic Republic of;
Roferon-A,
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Rosuvastatin calcium
University of Alexandria
2010 - NCT04328064 -
S78989
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
2012 - EUCTR2012-001125-27-IT Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Subcutaneous Ustekinumab
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02648581 France;
TA-650
Mitsubishi Tanabe Pharma Corporation
2012 Phase 3 NCT01532570 Japan;
Tacrolimus ointment
Assiut University
2019 - NCT05032248 Egypt;
Thalidomide
Shanghai Traditional Chinese Medicine Hospital
2021 Phase 0 ChiCTR2000037172 China;
Tocilizumab (TCZ)
Wenjie Zheng
2018 Phase 2 NCT03554161 China;
Topical Pentoxifylline Gel (Vehicle +PTX)
Silk Road Therapies, Inc.
2020 Phase 2 NCT04186559 United States;
Triamcinolone
The First Affiliated Hospital of Sun Yat-Sen University
2021 Phase 0 ChiCTR2100044593 China;
Triamcinolone Acetonide
Cairo University
2019 - NCT03771768 -
Ustekinumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2015 Phase 2 EUCTR2015-002190-37-FR France;
Veldona,
Nobel Pharmaceuticals
2006 Phase 2 NCT00483184 Turkey;
Water
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
XOMA 052
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
2012 - EUCTR2012-001125-27-IT Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2010 Phase 1/Phase 2 NCT01211977 United States;
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
3400935113276
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
8699505952864
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
AIN457
Novartis Farmacéutica, S.A.
2010 - EUCTR2009-013901-33-ES Austria;France;Germany;Greece;Spain;
2009 Phase 3 EUCTR2009-011237-27-ES Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharma Services AG
2010 - EUCTR2009-013901-33-GR Austria;France;Germany;Greece;Spain;
2010 - EUCTR2009-013901-33-FR Austria;France;Germany;Greece;Spain;
2010 - EUCTR2009-013901-33-DE Austria;France;Germany;Greece;Spain;
2009 - EUCTR2009-013901-33-AT Austria;France;Germany;Greece;Spain;
2009 - EUCTR2009-011237-27-DE Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-AT Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharma Services Ag
2009 - EUCTR2009-011237-27-HU Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-GR Austria;France;Germany;Greece;Hungary;Italy;Spain;
2009 - EUCTR2009-011237-27-FR Austria;France;Germany;Greece;Hungary;Italy;Spain;
Novartis Pharmaceuticals
2009 Phase 3 NCT00995709 Austria;Brazil;Egypt;France;Germany;Greece;Hong Kong;Hungary;India;Israel;Italy;Jordan;Korea, Republic of;Saudi Arabia;Singapore;Spain;Switzerland;Taiwan;Tunisia;Turkey;United States;
AMG 407
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
AMG-407
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
AMG407
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Adalimumab
AbbVie (prior sponsor, Abbott)
2010 Phase 3 NCT01243671 Japan;
State Key Laboratory of Ophthalmology, Zhongshan Ophthalmic Center, Sun Yat-Sen University
2020 Phase 4 ChiCTR1900027147 China;
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
The First Affiliated Hospital, College of Medicine, Zhejiang University
2021 Phase 4 ChiCTR2100045463 China;
Allogeneic Stem Cell Transplant
Northwestern University
2003 Phase 1 NCT00278512 United States;
Alpha interferon
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Anakinra
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2011 Phase 1/Phase 2 NCT01441076 United States;
Apremilast
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Amgen
2021 Phase 3 NCT04528082 France;Greece;Israel;Italy;Spain;Switzerland;United Kingdom;
2014 Phase 3 NCT02307513 France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Lebanon;Turkey;United States;
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Apremilast (CC-10004)
Amgen
2009 Phase 2 NCT00866359 Turkey;United States;
Autologous Stem Cell Transplant
Northwestern University
2003 Phase 1 NCT00278512 United States;
Autologous Stem Cell Transplantation
Tehran University of Medical Sciences
2007 Phase 1 NCT00550498 Iran, Islamic Republic of;
BFGF
Turkish Ophthalmology Society
2011 - NCT01720628 Turkey;
CC-10004
Amgen Inc.
2015 Phase 3 EUCTR2014-002108-25-DE France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
Celgene Corporation
2016 Phase 3 EUCTR2014-002108-25-GR France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
2015 Phase 3 EUCTR2014-002108-25-IT France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
Canakinumab
Novartis Pharmaceuticals
2016 Phase 2 NCT02756650 Turkey;
Colchicine
Ipekyolu Ilac Ltd. Sti
2019 Phase 2 NCT03888846 Turkey;
Tehran University of Medical Sciences
2002 Phase 2 NCT00700297 Iran, Islamic Republic of;
Cyclophosphamide
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03371095 -
Cyclosporin A
University Hospital Tuebingen
2004 Phase 3 NCT00167583 Germany;
Cyclosporine
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
Yokohama City University Hospital
2017 - JPRN-UMIN000025451 Japan;
Cyclosporine Pill
Peking Union Medical College Hospital
2017 Phase 3 NCT03209219 China;
Cytotoxic Combination
Tehran University of Medical Sciences
2006 Phase 2 NCT00664599 Iran, Islamic Republic of;
Daclizumab
National Eye Institute (NEI)
1999 Phase 2 NCT00001865 United States;
Dextrose
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
Entecavir
Saitama Medical University
2016 - JPRN-UMIN000020029 Japan;
Etanercept, Methotrexate, Prednisolone
Tehran University of Medical Sciences
2010 - NCT00931957 Iran, Islamic Republic of;
Flucinolone acetonide
Asan Medical Center
2008 Phase 4 NCT00720928 Korea, Republic of;
GSK1070806
Cambridge University Hospitals NHS Foundation Trust
2018 Phase 2 NCT03522662 United Kingdom;
Gevokizumab
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 Phase 3 NCT01965145 Korea, Republic of;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
XOMA (US) LLC
2014 Phase 3 NCT02258867 United States;
Golimumab (GOL)
Wenjie Zheng
2020 Phase 2 NCT04218565 China;
HUMIRA - 40 MG SOLUZIONE INIETTABILE USO SOTTOCUTANEO 1 SIRINGA PRERIEMPITA 0.8 ML + 1 TAMPONE IMBEVUTO DI ALCOL IN UN BLISTER
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Hemay005
Tianjin Hemay Pharmaceutical Co.,Ltd
2020 Phase 2 NCT04609397 China;
Hydroxychloroquine
Assiut University
2018 - NCT04022421 Egypt;
INFLECTRA - 100 MG - POLVERE PER CONCENTRATO PER SOLUZIONE PER INFUSIONE - USO ENDOVENOSO - FLACONCINO (VETRO) - 1 FLACONCINO
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Ilaris
University Hospital of Tübingen
2011 - EUCTR2010-024152-29-DE Germany;
Infliximab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
Assistance Publique - Hôpitaux de Paris
2018 Phase 3 NCT03371095 -
Janssen Korea, Ltd., Korea
2015 Phase 3 NCT02505568 Korea, Republic of;
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Yokohama City University Hospital
2017 - JPRN-UMIN000025451 Japan;
Interferon alpha-2a
The First Affiliated Hospital of Chongqing Medical University
2020 Phase 4 ChiCTR2000031637 China;
Interferon-alpha2a
University Hospital Tuebingen
2004 Phase 3 NCT00167583 Germany;
Intravitreal Infliximab
Cairo University
2013 Phase 1/Phase 2 NCT02620618 -
J1081
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Low-dose IL-2
Peking University People's Hospital
2019 Phase 2 NCT04065672 China;
MEDROL - 4 MG COMPRESSE 30 COMPRESSE
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
METILPREDNISOLONE SODIO SUCCINATO
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Methylorednisolone
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
OTEZLA - 10 MG + 20 MG + 30 MG COMPRESSA RIVESTITA CON FILM USO ORALE - BLISTER (PVC/ALU) IN UN ASTUCCIO - 4 COMPRESSE DA 10 MG + 4 COMPRESSE DA 20 MG +19 COMPRESSE DA
AMGEN INC.
2021 Phase 3 EUCTR2019-002787-27-IT France;Greece;Israel;Italy;Netherlands;Switzerland;
Otezla
Amgen Inc.
2021 Phase 3 EUCTR2019-002787-27-GR France;Greece;Israel;Netherlands;Switzerland;
2015 Phase 3 EUCTR2014-002108-25-DE France;Germany;Greece;Israel;Italy;Japan;Korea, Republic of;Turkey;United States;
- Phase 3 EUCTR2019-002787-27-NL France;Greece;Israel;Italy;Netherlands;Spain;Switzerland;United Kingdom;
- Phase 3 EUCTR2019-002787-27-FR France;Israel;Netherlands;Switzerland;
Pentoxifylline
Ipekyolu Ilac Ltd. Sti
2019 Phase 2 NCT03888846 Turkey;
Prednisolone
Castle Study Group
2013 - JPRN-UMIN000012469 Japan;
Remicade
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
- Phase 2 EUCTR2017-002264-41-FR France;
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
RhumAb to Il-17A (IgG1-k-class)
Novartis Pharma Services Ag
2009 - EUCTR2009-011237-27-FR Austria;France;Germany;Greece;Hungary;Italy;Spain;
Rituximab
Tehran University of Medical Sciences
2006 Phase 2 NCT00664599 Iran, Islamic Republic of;
Roferon-A,
The University of Liverpool
2016 Phase 3 EUCTR2014-005390-36-GB United Kingdom;
Rosuvastatin calcium
University of Alexandria
2010 - NCT04328064 -
S78989
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
2012 - EUCTR2012-001125-27-IT Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
SOLU MEDROL - 40 MG/ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE A DOPPIA CAMERA DA 40 MG/ML
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
SOLU MEDROL - 500 MG/8 ML POLVERE E SOLVENTE PER SOLUZIONE INIETTABILE 1 FLACONE DI POLVERE DA 500 MG+ FIALA SOLVENTE DA 8 ML
AZIENDA OSPEDALIERO-UNIVERSITARIA PISANA
2017 Phase 3 EUCTR2017-000845-39-IT Italy;
Subcutaneous Ustekinumab
Assistance Publique - Hôpitaux de Paris
2017 Phase 2 NCT02648581 France;
TA-650
Mitsubishi Tanabe Pharma Corporation
2012 Phase 3 NCT01532570 Japan;
Tacrolimus ointment
Assiut University
2019 - NCT05032248 Egypt;
Thalidomide
Shanghai Traditional Chinese Medicine Hospital
2021 Phase 0 ChiCTR2000037172 China;
Tocilizumab (TCZ)
Wenjie Zheng
2018 Phase 2 NCT03554161 China;
Topical Pentoxifylline Gel (Vehicle +PTX)
Silk Road Therapies, Inc.
2020 Phase 2 NCT04186559 United States;
Triamcinolone
The First Affiliated Hospital of Sun Yat-Sen University
2021 Phase 0 ChiCTR2100044593 China;
Triamcinolone Acetonide
Cairo University
2019 - NCT03771768 -
Ustekinumab
ASSISTANCE PUBLIQUE - HOPITAUX DE PARIS (AP-HP)
2015 Phase 2 EUCTR2015-002190-37-FR France;
Veldona,
Nobel Pharmaceuticals
2006 Phase 2 NCT00483184 Turkey;
Water
Tehran University of Medical Sciences
2010 Phase 4 NCT01306955 Iran, Islamic Republic of;
XOMA 052
INSTITUT DE RECHERCHES INTERNATIONALES SERVIER
2012 - EUCTR2012-001125-27-IT Brazil;China;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Institut de Recherches Internationales Servier
2013 Phase 3 EUCTR2012-001125-27-PT Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2013 Phase 3 EUCTR2012-001125-27-GB Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-GR Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
2012 - EUCTR2012-001125-27-DE Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
Laboratorios Servier S.L.
2012 - EUCTR2012-001125-27-ES Brazil;China;France;Germany;Greece;Hong Kong;India;Italy;Korea, Republic of;Portugal;Russian Federation;Saudi Arabia;Spain;Tunisia;Turkey;United Kingdom;
National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)
2010 Phase 1/Phase 2 NCT01211977 United States;